Application of forsythiaside A in preparation of drugs for preventing and treating cardiovascular and cerebrovascular diseases

A technology of forsythiaside and medicine is applied in the application field of forsythiaside A in the preparation of medicines for preventing and treating cardiovascular and cerebrovascular diseases, which can solve the problems of never-before-seen medicines for cardiovascular and cerebrovascular diseases, and achieve the effect of strong pharmacological action

Active Publication Date: 2012-06-27
山西华卫药业有限公司
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] According to reports, forsythiaside A has antiviral, antibacterial, antipyretic, analgesic, hepatoprotective, antioxidative, anti-inflammatory and anti-endotoxin activities, but there has never been a report on the preparation of drugs for the prevention and treatment of cardiovascular and cerebrovascular diseases.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of forsythiaside A in preparation of drugs for preventing and treating cardiovascular and cerebrovascular diseases
  • Application of forsythiaside A in preparation of drugs for preventing and treating cardiovascular and cerebrovascular diseases
  • Application of forsythiaside A in preparation of drugs for preventing and treating cardiovascular and cerebrovascular diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0013] Example 1 Effect of forsythiaside A on ADP-induced platelet aggregation in rats in vitro

[0014] Blood was collected from the abdominal aorta of rats (Wistar, clean level II), anticoagulated with 3.8% sodium citrate 1:9, 500r·min -1 Centrifuge for 5 minutes to take the supernatant to obtain platelet-rich plasma (PRP). The remaining part 2500r·min -1 After centrifugation for 10 min, the supernatant was taken to obtain platelet-poor plasma (PPP). Dilute PRP with PPP to bring platelet count to 3×10 11 / L.

[0015] Take 265 μL PRP and place it in a turbidimetric tube, add forsythiaside (content greater than 95%) solution (final concentration is 2.1, 2.6, 3.1, 3.6, 4.1, 6.2, 8.2mmol·L -1 ) 20 μL, add an equal volume of normal saline to the blank control tube, pre-warm at 37°C for 3 minutes, start the platelet aggregation coagulation factor analyzer, and quickly add 2mmol·L -1 ADP15μL, record the platelet aggregation curve, and calculate the inhibition rate of platelet...

Embodiment 2

[0022] Example 2 Effect of Forsythiaside A on Rat Plasma Prothrombin Time (PT)

[0023] Rat abdominal aorta blood collection, 3.8% sodium citrate 1:9 anticoagulant, 2500r·min -1 After centrifugation for 10 min, the supernatant was taken to obtain PPP. Pre-warm the PT reagent in the reagent pre-warming well at 37°C for more than 10 minutes, and shake well before use. Take 50 μL of PPP and place it in a turbidimetric tube, add forsythiaside A solution (final concentration is 8.3, 12.5, 16.6 mmol L -1 ) 30 μL, add an equal volume of normal saline to the control tube, pre-warm at 37 °C for 180 seconds, add 100 μL of PT reagent at 37 °C, start the instrument immediately for automatic testing, and record the results.

[0024] The results showed that: Forsythiaside can significantly prolong the isolated plasma PT of rats, and the prolonging effect is more obvious with the increase of the dose (Table 2). The final concentration is 16.6mmol·L -1 Forsythiaside prolongs PT for more t...

Embodiment 3

[0028] Example 3 Effect of Forsythiaside A on Rat Plasma Thrombin Time (TT)

[0029] The PPP preparation method is the same as above, take the TT reagent out of the refrigerator and let it stand at room temperature for 10 minutes, and the temperature is equilibrated to room temperature. Take 80 μL of PPP and place it in a turbidimetric tube, add forsythiaside solution (final concentration is 7.1, 10.7, 14.2 mmol L -1 ) 30 μL, add an equal volume of normal saline to the control tube, pre-warm at 37°C for 180 seconds, add 100 μL of TT reagent, immediately start the instrument for automatic testing, and record the results.

[0030] The results showed that: forsythiaside A can significantly prolong the isolated plasma TT in rats, and there is an obvious dose-effect relationship (Table 3).

[0031] The influence of table 3 forsythiaside A on rat isolated plasma TT ( n=6)

[0032]

[0033] *P<0.05 vs NS, ***P<0.001 vs NS

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention proves that forsythiaside A has the function of inhibiting platelet aggregation and simultaneously has the obvious anticoagulation role by studying the impacts of the forsythiaside A on ADP-induced platelet aggregation in vitro of rats, the impacts on plasma prothrombin time (PT) of the rats and the impacts on plasma thrombin time (TT) of the rats. The forsythiaside A can be used for preparing drugs for preventing and treating cardiovascular and cerebrovascular diseases. The forsythiaside A can also be used as a food additive for preparing functional foods for preventing and treating the cardiovascular and cerebrovascular diseases.

Description

technical field [0001] The invention relates to forsythiaside A, specifically the application of forsythiaside A in the preparation of drugs for preventing and treating cardiovascular and cerebrovascular diseases. Background technique [0002] Forsythoside A (Forsythoside A) can be obtained by extracting Forsythia Suspensa (Thunb.) Vahl. from Oleaceae. The structural formula is: [0003] [0004] Molecular formula C 29 h 36 o 15 , with a molecular weight of 624, light yellow powder compound, easily soluble in water, ethanol, methanol, etc. [0005] It is reported that forsythiaside A has antiviral, antibacterial, antipyretic, analgesic, hepatoprotective, antioxidative, anti-inflammatory and anti-endotoxin activities. However, there has never been any report on the preparation of drugs for the prevention and treatment of cardiovascular and cerebrovascular diseases. Contents of the invention [0006] The purpose of the present invention is to expand the use of forsyt...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/7032A61P9/00A61P7/02A61P9/10A23L1/30A23L33/105
Inventor 张立伟柴秋彦
Owner 山西华卫药业有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap